Biomarker adaptive designs in clinical trials

Translational Cancer Research

Volumn 3, Issue 3, 2014, Pages 279-292

  Chen, James J ^a   Lu, Tzu Pin ^a,b   Chen, Dung Tsa ^c   Wang, Sue Jane ^d  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Adaptive signature design (ASD); Classification; Personalized medicine; Predictive classifier; Subgroup analysis; Subgroup identification

Indexed keywords

EID: 84962642073     PISSN: 2218676X     EISSN: 22196803     Source Type: Journal    
DOI: 10.3978/j.issn.2218-676X.2014.05.04     Document Type: Review

References (73)

1. Nesbitt JC, Putnam JB Jr, Walsh GL, et al. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg 1995;60:466-72.
2. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet 2000;355:479-85.
3. Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 2010;102:464-74.
4. Balis FM. Evolution of anticancer drug discovery and the role of cell-based screening. J Natl Cancer Inst 2002;94:78-9.
5. Schilsky RL. End points in cancer clinical trials and the drug approval process. Clin Cancer Res 2002;8:935-8.
6. Rothenberg ML, Carbone DP, Johnson DH. Improving the evaluation of new cancer treatments: challenges and opportunities. Nat Rev Cancer 2003;3:303-9.
7. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-958
8. Lassere MN, Johnson KR, Boers M, et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol 2007;34:607-15.
9. Jenkins M, Flynn A, Smart T, et al. A statistician's perspective on biomarkers in drug development. Pharm Stat 2011;10:494-507.
10. Buyse M, Michiels S, Sargent DJ, et al. Integrating biomarkers in clinical trials. Expert Rev Mol Diagn 2011;11:171-82.
11. Wang SJ. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI. Pharm Stat 2007;6:283-96.
12. Mizuarai S, Irie H, Kotani H. Gene expression-based pharmacodynamic biomarkers: the beginning of a new era in biomarker-driven anti-tumor drug development. Curr Mol Med 2010;10:596-607.
13. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13.
14. Baker SG, Kramer BS. A perfect correlate does not a surrogate make. BMC Med Res Methodol 2003;3:16.
15. Weir CJ, Walley RJ. Statistical evaluation of biomarkers as surrogate endpoints: a literature review. Stat Med 2006;25:183-203.
16. Sargent DJ, Conley BA, Allegra C, et al. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23:2020-7.
17. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 2009;27:4027-34.
18. Wang SJ, O'Neill RT, Hung HM. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat 2007;6:227-44.
19. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: one size does not fit all. J Biopharm Stat 2009;19:530-42.
20. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005;11:7872-8.
21. Wang SJ, Hung HM, O'Neill RT. Adaptive patient enrichment designs in therapeutic trials. Biom J 2009;51:358-74.
22. Scher HI, Nasso SF, Rubin EH, et al. Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics. Clin Cancer Res 2011;17:6634-40.
23. US FDA. Draft Drug Diagnostic Co-Development Preliminary Concept Paper. Available online: http://www.fda.gov/downloads/drugs/scienceresearch/researchareas/pharmacogenetics/ucm116689.pdf
24. US FDA. In Vitro Companion Diagnostic Devices. Available online: http://www.fda.gov/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm262292.htm
25. Baek S, Tsai CA, Chen JJ. Development of biomarker classifiers from high-dimensional data. Brief Bioinform 2009;10:537-46.
26. McCullagh P, Nelder JA. eds. Generalized Linear Model, 2nd Edition. London: Chapman Hall, 1989.
27. Cox DR, Oakes D. eds. Analysis of survival data. London: Chapman Hall/CRC, 1984.
28. Lee JW, Lee JB, Park M, et al. An extensive comparison of recent classification tools applied to microarray data. Comput Stat Data An 2005;48:869-85.
29. Moon H, Ahn H, Kodell RL, et al. Ensemble methods for classification of patients for personalized medicine with high-dimensional data. Artif Intell Med 2007;41:197-207.
30. Breiman L. Random forest. Mach Learn 2001;45:5-32.
31. Vapnik V. eds. The Nature of Statistical Learning Theory. New York: Springer, 1995.
32. Guyon I, Weston J, Barnhill S, et al. Gene selection for cancer classification using support vector machines. Mach Learn 2002;46:389-422.
33. Dudoit S, Fridlyand J, Speed T. Comparison of discrimination methods for the classification of tumors using gene expression data. J Am Stat Assoc 2002;97:77-87.
34. Chen HC, Kodell RL, Cheng KF, et al. Assessment of performance of survival prediction models for cancer prognosis. BMC Med Res Methodol 2012;12:102.
35. Chen DT, Hsu YL, Fulp WJ, et al. Prognostic and predictive value of a malignancy-risk gene signature in early-stage non-small cell lung cancer. J Natl Cancer Inst 2011;103:1859-70.
36. Jiang W, Freidlin B, Simon R. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 2007;99:1036-43.
37. Freidlin B, Jiang W, Simon R. The cross-validated adaptive signature design. Clin Cancer Res 2010;16:691-8.
38. Wang S, Li MC. Impacts of predictive genomic classifier performance on subpopulation-specific treatment effects assessment. Stat Biosci 2014.
39. Brookes ST, Whitely E, Egger M, et al. Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test. J Clin Epidemiol 2004;57:229-36.
40. Pocock SJ, Hughes MD, Lee RJ. Statistical problems in the reporting of clinical trials. A survey of three medical journals. N Engl J Med 1987;317:426-32.
41. Yusuf S, Wittes J, Probstfield J, et al. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-8.
42. Assmann SF, Pocock SJ, Enos LE, et al. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet 2000;355:1064-9.
43. Song Y, Chi GY. A method for testing a prespecified subgroup in clinical trials. Stat Med 2007;26:3535-49.
44. Millen BA. A statistical framework for decision making in confirmatory multipopulation tailoring clinical trials. Drug Inf J 2012;46:647-56.
45. Wang SJ, Hung HM. A regulatory perspective on essential considerations in design and analysis of subgroups when correctly classified. J Biopharm Stat 2014;24:19-41.
46. Marcus R, Peritz E, Gabriel K. On closed testing procedure with special reference to ordered analysis of variance. Biometrika 1976;63:655-60.
47. Benjamin Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Roy Stat Soc B 1995;57:289-300.
48. Benjamin Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Anna Stat 2001;29:1165-88.
49. Storey J. A direct approach to false discovery rates. J Roy Stat Soc B 2002;64:479-98.
50. Tsai CA, Hsueh HM, Chen JJ. Estimation of false discovery rates in multiple testing: application to gene microarray data. Biometrics 2003;59:1071-81.
51. Polley MY, Freidlin B, Korn EL, et al. Statistical and practical considerations for clinical evaluation of predictive biomarkers. J Natl Cancer Inst 2013;105:1677-83.
52. Chen JJ, Roberson PK, Schell MJ. The false discovery rate: a key concept in large-scale genetic studies. Cancer Control 2010;17:58-62.
53. Lin WJ, Chen JJ. Class-imbalanced classifiers for high-dimensional data. Brief Bioinform 2013;14:13-26.
54. Chen JJ, Tsai CA, Young JF, et al. Classification ensembles for unbalanced class sizes in predictive toxicology. SAR QSAR Environ Res 2005;16:517-29.
55. Justice AC, Covinsky KE, Berlin JA. Assessing the generalizability of prognostic information. Ann Intern Med 1999;130:515-24.
56. Chen HC, Chen JJ. Assessment of reproducibility of cancer survival risk predictions across medical centers. BMC Med Res Methodol 2013;13:25.
57. Ramaswamy S, Ross KN, Lander ES, et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.
58. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001;98:13790-5.
59. Liu J, Blackhall F, Seiden-Long I, et al. Modeling of lung cancer by an orthotopically growing H460SM variant cell line reveals novel candidate genes for systemic metastasis. Oncogene 2004;23:6316-24.
60. Blackhall FH, Wigle DA, Jurisica I, et al. Validating the prognostic value of marker genes derived from a non-small cell lung cancer microarray study. Lung Cancer 2004;46:197-204.
61. Parmigiani G, Garrett-Mayer ES, Anbazhagan R, et al. A cross-study comparison of gene expression studies for the molecular classification of lung cancer. Clin Cancer Res 2004;10:2922-7.
62. Lu TP, Chuang EY, Chen JJ. Identification of reproducible gene expression signatures in lung adenocarcinoma. BMC Bioinformatics 2013;14:371.
63. Lau SK, Boutros PC, Pintilie M, et al. Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol 2007;25:5562-9.
64. Shi L, Reid LH, Jones WD, et al. The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 2006;24:1151-61.
65. Chen JJ, Hsueh HM, Delongchamp RR, et al. Reproducibility of microarray data: a further analysis of microarray quality control (MAQC) data. BMC Bioinformatics 2007;8:412.
66. Harrell FE Jr, Califf RM, Pryor DB, et al. Evaluating the yield of medical tests. JAMA 1982;247:2543-6.
67. Kattan MW. Evaluating a new marker's predictive contribution. Clin Cancer Res 2004;10:822-4.
68. Newson R. Confidence intervals for rank statistics: Somers' D and extensions. Stata J 2006;6:309-34.
69. Gerds TA, Schumacher M. Consistent estimation of the expected Brier score in general survival models with right-censored event times. Biom J 2006;48:1029-40.
70. Bair E, Tibshirani R. Semi-supervised methods to predict patient survival from gene expression data. PLoS Biol 2004;2:E108.
71. Heagerty PJ, Lumley T, Pepe MS. Time-dependent ROC curves for censored survival data and a diagnostic marker. Biometrics 2000;56:337-44.
72. Schemper M. Predictive accuracy and explained variation. Stat Med 2003;22:2299-308.
73. Schemper M. The relative importance of prognostic factors in studies of survival. Stat Med 1993;12:2377-82.